Effect of intravitreal bevacizumab injection before vitrectomy on proliferative diabetic retinopathy
10.3969/j.issn.1672-5123.2010.09.004
- VernacularTitle:玻璃体腔内注射贝伐单抗对增生性糖尿病视网膜病变玻璃体手术的影响
- Author:
Cai-Rui, LI
;
Shu-Guang, SUN
;
Wei, HONG
- Publication Type:Journal Article
- Keywords:
bevacizumab;
vascular endothelial growth factor;
proliferative diabetic retinopathy;
vitrectomy
- From:
International Eye Science
2010;10(9):1654-1656
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To evaluate the effect of intravitreal bevacizumab (IVB) injection 1 week before pars plana vitrectomy (PPV) in proliferative diabetic retinopathy (PDR) patients. METHODS: A retrospective research was done on 46 PDR patients who were divided into PPV group (n=28) and IVB group (n=18, PPV with preoperative IVB). Bevacizumab was injected 1 week before PPV. Main outcome measures were visual acuity, incidence of iatrogenic retinal breaks, intraoperative and postoperative bleeding. RESULTS: At 1 month after surgery, visual acuity in PPV (82.1%) and IVB group (88.9%) improved significantly (P<0.01) and the difference between the two groups was not significant. Iatrogenic retinal breaks were reported in 18 cases (64.3%) in PPV group and 4 cases (22.2%) in IVB group (P<0.05). Intraoperative bleeding was encountered in all cases in PPV group and 7 cases (39%) in IVB group (P<0.01). Postoperative bleeding was reported in 9 cases (32.1%) in PPV group and none in IVB group (P<0.01). CONCLUSION: IVB injection before PPV is helpful in reducing iatrogenic retinal breaks, intraoperative and postoperative bleeding in PDR patients.
